8 Major subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.12.2020 |
|
31.12.2019 |
||
|
|
|
|
|
|
|
|
|
|
|
Share of |
|
Share of |
||
|
Company name |
|
Domicile |
|
Purpose |
|
Currency |
|
Share capital/Nominal capital |
|
Capital |
Voting rights |
|
Capital |
Voting rights |
|
Fully consolidated companies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bellevue Group AG |
|
Küsnacht, Switzerland |
|
Holding |
|
CHF |
|
1 346 143 |
|
Parent company |
|
Parent company |
||
|
Bellevue Asset Management AG |
|
Küsnacht, Switzerland |
|
Asset Management |
|
CHF |
|
1 750 000 |
|
100% |
100% |
|
100% |
100% |
|
Bellevue Asset Management (Deutschland) GmbH |
|
Frankfurt am Main, Germany |
|
Asset Management |
|
EUR |
|
25 000 |
|
100% |
100% |
|
100% |
100% |
|
Bellevue Asset Management (UK) Limited |
|
London, UK |
|
Asset Management |
|
GBP |
|
50 000 |
|
100% |
100% |
|
100% |
100% |
|
Asset Management BaB N.V. |
|
Curaçao |
|
Asset Management |
|
USD |
|
6 001 |
|
100% |
100% |
|
100% |
100% |
|
Bellevue Research Inc. |
|
Boston, USA |
|
Research |
|
USD |
|
100 |
|
100% |
100% |
|
100% |
100% |
|
BB Biotech Ventures G.P. |
|
Guernsey |
|
Investment Advisor |
|
GBP |
|
10 000 |
|
100% |
100% |
|
100% |
100% |
|
BB Pureos Bioventures GP Limited |
|
Guernsey |
|
Investment Advisor |
|
GBP |
|
60 000 |
|
99% |
99% |
|
99% |
99% |
|
StarCapital AG |
|
Oberursel, Germany |
|
Asset Management |
|
EUR |
|
540 000 |
|
100% |
100% |
|
100% |
100% |
|
adbodmer AG |
|
Horgen, Switzerland |
|
Investment Advisor |
|
CHF |
|
100 000 |
|
100% |
100% |
|
100% |
100% |
|
Bellevue Private Markets AG |
|
Küsnacht, Switzerland |
|
Holding |
|
CHF |
|
1 000 000 |
|
100% |
100% |
|
100% |
100% |
|
Realwerk AG 1) |
|
Horgen, Switzerland |
|
Investment Advisor |
|
CHF |
|
100 000 |
|
100% |
100% |
|
0% |
0% |
|
Bellevue Komplementär AG 2) |
|
Küsnacht, Switzerland |
|
Asset Management |
|
CHF |
|
200 000 |
|
100% |
100% |
|
0% |
0% |
|
Bank am Bellevue AG 3) |
|
Küsnacht, Switzerland |
|
Bank |
|
CHF |
|
25 000 000 |
|
0% |
0% |
|
100% |
100% |
|
Bellevue Investment Advisers AG 3) |
|
Zürich, Switzerland |
|
Asset Management |
|
CHF |
|
500 000 |
|
0% |
0% |
|
100% |
100% |
1) The company was acquired on 7.1.2020.
2) The company was founded on 10.12.2020.
3) The company was selled on 30.4.2020.
Minority shareholders’ equity ownership of BB Pureos Bioventures GP Limited is 1%. Due to the non-materiality of this ownership with respect to the overall Bellevue Group’s equity and comprehensive income, no separate disclosure of minority shareholders has been published on the Group’s financial statements.